ASH 2016

A Glimpse of ASH

A Glimpse of ASH

By

Dr Isabel Cunningham discusses some of the important studies presented at the 2016 ASH meeting.

DRd Superior to Rd Regardless of Time Since Last Therapy in Myeloma

DRd Superior to Rd Regardless of Time Since Last Therapy in Myeloma

By

Daratumumab plus lenalidomide and dexamethasone (DRd) is superior to lenalidomide plus dexamethasone (Rd).

Idarubicin + HDAC ± Vorinostat Not Superior to 7+3 in AML

Idarubicin + HDAC ± Vorinostat Not Superior to 7+3 in AML

By

Idarubicin plus high-dose cytarabine (HDAC) with or without vorinostat was not superior to 7+3 chemotherapy.

DVd Superior to Vd Regardless of Prior Lines of Therapy in Myeloma

DVd Superior to Vd Regardless of Prior Lines of Therapy in Myeloma

By

Daratumumab plus bortezomib and dexamethasone (DVd) is superior to bortezomib plus dexamethasone (Vd).

Nilotinib Discontinuation Following Deep Molecular Response

Nilotinib Discontinuation Following Deep Molecular Response

By

Some patients with chronic myeloid leukemia (CML) who have maintained deep molecular responses for at least 2 years can safely discontinue nilotinib.

No Impact of Detectable Disease on MRFS After Imatinib Cessation in CML

No Impact of Detectable Disease on MRFS After Imatinib Cessation in CML

By

There were no differences in molecular relapse-free survival between patients with prior 4.5 log reduction but detectable disease and those with undetectable disease

TKI Cessation Appears Feasible, Safe in Patients With CML

TKI Cessation Appears Feasible, Safe in Patients With CML

By

Tyrosine kinase inhibitor (TKI) cessation appears feasible and safe in patients with chronic myeloid leukemia in chronic phase (CML-CP).

CML-CP: Second TKI Discontinuation Safe and Successful

CML-CP: Second TKI Discontinuation Safe and Successful

By

Tyrosine kinase inhibitors (TKIs) can be safely and successfully discontinued a second time despite failing first discontinuation.

Imatinib Generics Appear Non-inferior to Gleevec Brand Formulation in CML-CP

Imatinib Generics Appear Non-inferior to Gleevec Brand Formulation in CML-CP

By

Generic formulations of imatinib appear to be non-inferior to Novartis's Gleevec brand formulation with respect to clinical efficacy and tolerability.

ATRA + Arsenic Trioxide Active in Acute Promyelocytic Leukemia

ATRA + Arsenic Trioxide Active in Acute Promyelocytic Leukemia

By

All-trans retinoic acid (ATRA) plus arsenic trioxide with or without chemotherapy induces high remission rates.

Lower Intensity Intensification Therapy in Childhood ALL

Lower Intensity Intensification Therapy in Childhood ALL

By

Pediatric patients with acute lymphoblastic lymphoma (ALL) at standard risk for relapse do not benefit from lower-intensity, delayed intensification therapy.

Obinutuzumab-based Therapy Prolongs PFS in Untreated Follicular Lymphoma

Obinutuzumab-based Therapy Prolongs PFS in Untreated Follicular Lymphoma

By

Obinutuzumab-based induction and maintenance chemoimmunotherapy significantly improved progression-free survival.

Serum Free Light Chain Responses Better for Predicting Clinical Outcomes

Serum Free Light Chain Responses Better for Predicting Clinical Outcomes

By

Serum free light chain measurements correlate more closely with clinical outcomes than urine assessments in patients with light chain multiple myeloma.

Study Highlights Importance of Achieving CR After Intensive Therapy for AML

Study Highlights Importance of Achieving CR After Intensive Therapy for AML

By

Patients with acute myeloid leukemia (AML) who achieve complete remission have improved overall survival.

No Induction Therapy Superior to Another for Higher-risk AML, MDS

No Induction Therapy Superior to Another for Higher-risk AML, MDS

By

In higher-risk patients who fail hypomethylating agent treatment, no induction strategy is superior to another with respect to outcomes and safety.

Brentuximab Vedotin Superior to Standard of Care Options in CTCL

Brentuximab Vedotin Superior to Standard of Care Options in CTCL

By

Treatment with brentuximab vedotin is associated with superior clinical outcomes compared with standard of care options.

Higher Idarubicin Dose During Consolidation Improves Leukemia-free Survival in AML

Higher Idarubicin Dose During Consolidation Improves Leukemia-free Survival in AML

By

A higher dose of idarubicin during consolidation therapy improves leukemia-free survival without increasing non-hematologic toxicity.

Condensed HDAC Schedule Superior to Standard Schedule in AML

Condensed HDAC Schedule Superior to Standard Schedule in AML

By

Consolidation therapy with a condensed schedule of high-dose cytarabine (HDAC) is superior to a standard schedule.

Chemo-free Induction Efficacious in Younger Patients With Mantle Cell Lymphoma

Chemo-free Induction Efficacious in Younger Patients With Mantle Cell Lymphoma

By

Chemotherapy-free induction with ibrutinib and rituximab is efficacious and well-tolerated among young patients.

VcR-CVAD Regimen Induces Durable Remissions in Mantle Cell Lymphoma

VcR-CVAD Regimen Induces Durable Remissions in Mantle Cell Lymphoma

By

Incorporation of bortezomib into VcR-CVAD followed by rituximab maintenance demonstrated high rates of durable remissions.

Venetoclax + LDAC Appears Active, Safe in Older Patients With AML

Venetoclax + LDAC Appears Active, Safe in Older Patients With AML

By

Venetoclax in combination with low-dose cytarabine appears active in older, treatment-naive patients with acute myeloid leukemia.

Rituximab Maintenance Prolongs Survival Among Younger Patients With Mantle Cell Lymphoma

Rituximab Maintenance Prolongs Survival Among Younger Patients With Mantle Cell Lymphoma

By

Rituximab maintenance following autologous hematopoietic cell transplantation prolongs survival among younger patients with mantle cell lymphoma.

Brentuximab Vedotin + RCHP Active in High-intermediate/High Risk DLBCL

Brentuximab Vedotin + RCHP Active in High-intermediate/High Risk DLBCL

By

Brentuximab vedotin in combination with RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) is active as a frontline therapy.

Study Identifies Ultra-high Risk Category of Patients With DLBCL

Study Identifies Ultra-high Risk Category of Patients With DLBCL

By

Ultra-high risk category of patients with diffuse large B-cell lymphoma (DLBCL) who have dismal outcomes on existing therapies.

Nivolumab + Ibrutinib Active in Relapsed/Refractory CLL and Richter Transformation

Nivolumab + Ibrutinib Active in Relapsed/Refractory CLL and Richter Transformation

By

The combination of nivolumab and ibrutinib is active in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

Clonal Hematopoiesis Increases Risk of Therapy-related Myeloid Malignancies

Clonal Hematopoiesis Increases Risk of Therapy-related Myeloid Malignancies

By

Clonal hematopoiesis at the time of primary cancer diagnosis was associated with a significantly increased risk of therapy-related myeloid neoplasm development.

Lenalidomide Maintenance Efficacious for High Risk CLL After Chemoimmunotherapy

Lenalidomide Maintenance Efficacious for High Risk CLL After Chemoimmunotherapy

By

Lenalidomide is a feasible and efficacious option as maintenance therapy for patients with high risk chronic lymphocytic leukemia (CLL).

Anti-CD22 CAR T Cell Therapy Active in R/R Acute Lymphoblastic Leukemia

Anti-CD22 CAR T Cell Therapy Active in R/R Acute Lymphoblastic Leukemia

By

Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy is safe, feasible, and clinically active in children and young adults.

Better Treatment Options Needed for Patients With CML in Blast Phase

Better Treatment Options Needed for Patients With CML in Blast Phase

By

Despite therapeutic advancements in the treatment of chronic myeloid leukemia (CML), patients who transform to blast phase (CML-BP) have a poor outcome.

ASH 2016: What To Watch in San Diego

ASH 2016: What To Watch in San Diego

By

Next week, researchers will meet in San Diego, California, at the American Society of Hematology (ASH) 58th Annual Meeting & Exposition.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs